Since commercial antibodies target the C-terminal domain of DCLK1, the unique oncogenic functions of DCLK1 isoforms, as well as their possible contribution to tumor growth in cancer tissues like CRC, need to be investigated further. This evidence concerns the gene DCLK1 and cancer.